ClinicalTrials.gg
Not yet recruitingNCT07450287CardioNETPOLUpdated Mar 4, 2026

CardioNETPOL National Registry of Carcinoid Heart Disease

An observational study in Carcinoid Heart Disease, Neuroendocrine Tumors and Carcinoid Syndrome, sponsored by National Institute of Cardiology, Warsaw, Poland. Not yet recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by National Institute of Cardiology, Warsaw, Poland · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
120
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 22 studies in Neuroendocrine Tumors with a site in Poland — 4 open to participants now, 6 under way, 3 of them phase 3. Neuroendocrine Tumors · Poland.

Started
2026
with 1 other
Observational
7 of 22
2 open now
Registered
21st of 22
by date

Among the 22 studies in Neuroendocrine Tumors with a site in Poland, this one is one of 2 that started in 2026, is one of 7 observational ones, and was the 21st registered.

Neuroendocrine Tumors

544 studies on the registry are indexed under Neuroendocrine Tumors; 136 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

4 of the 22 studies in Neuroendocrine Tumors with a site in Poland are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 111 Neuroendocrine Tumors studies recruiting now, 72 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Neuroendocrine Tumors with a site in Poland, or all of them as a file.
02

Study summary

Carcinoid tumors are neuroendocrine tumors (NETs), most commonly originating from the gastrointestinal tract, that may secrete bioactive substances such as serotonin. Persistent exposure to these mediators can lead to carcinoid syndrome and, in up to 50% of patients, carcinoid heart disease (CHD). CHD is characterized by fibrotic degeneration of cardiac valves, predominantly right-sided, resulting in progressive valvular dysfunction and a significant increase in mortality.

The mechanisms underlying selective cardiac involvement and predictors of disease progression remain incompletely understood. In addition, optimal timing and selection of surgical versus transcatheter valve interventions, particularly in high-risk patients, require further clarification.

This multicenter, retrospective observational registry aims to identify and characterize patients with carcinoid heart disease and at least moderate valvular involvement. CHD is defined by confirmed neuroendocrine tumor, echocardiographic evidence of ≥ moderate valvular disease with features of fibrosis, elevated NT-proBNP (>260 ng/L), and histopathological confirmation when available.

Approximately 100-120 consecutive patients will be enrolled over 12 months. Standardized data collection will include detailed echocardiographic assessment, demographic and clinical characteristics, cardiovascular risk factors, comorbidities, tumor features, oncological treatment history, and cardiac management strategies.

The primary objective is to describe the clinical profile and management of patients with CHD in a real-world multicenter setting. Secondary objectives include identifying factors associated with advanced valvular dysfunction and evaluating eligibility and outcomes of transcatheter valve therapies. The registry is expected to improve risk stratification and support clinical decision-making in carcinoid heart disease.

Read the detailed description

Carcinoid tumors are well-differentiated neuroendocrine neoplasms (NETs) capable of secreting vasoactive and fibrogenic substances, including serotonin, tachykinins, histamine, and prostaglandins. Persistent exposure to these mediators, particularly in the presence of hepatic metastases bypassing first-pass metabolism, may lead to the development of carcinoid syndrome and, in a substantial proportion of patients, carcinoid heart disease (CHD). Cardiac involvement is characterized by plaque-like fibrotic thickening of the endocardium, predominantly affecting right-sided heart valves, leading to leaflet retraction, reduced mobility, and progressive valvular regurgitation and/or stenosis. Over time, this process results in right ventricular volume overload, chamber dilation, heart failure symptoms, and reduced survival.

Although CHD represents a major determinant of prognosis in patients with carcinoid syndrome, important gaps remain in understanding its natural history, predictors of progression, and optimal management strategies. The incidence and severity of cardiac involvement vary considerably between individuals with similar oncologic profiles. Biomarkers such as NT-proBNP are widely used for screening and monitoring, but their integration with imaging findings and clinical variables in risk stratification requires further refinement. In addition, advances in oncological therapy have improved overall survival in NET patients, thereby increasing the clinical relevance of long-term cardiovascular complications.

Surgical valve replacement has traditionally been the standard treatment for advanced valvular dysfunction in CHD. However, many patients are at elevated operative risk due to metastatic disease burden, hepatic dysfunction, malnutrition, or other comorbidities. Emerging transcatheter valve therapies, including bicaval valve implantation and transcatheter tricuspid valve replacement or repair, offer potential alternatives for selected high-risk patients. Data regarding patient selection, anatomical suitability, procedural feasibility, and outcomes in the specific context of CHD remain limited.

This multicenter, retrospective, observational registry is designed to provide a comprehensive characterization of patients with carcinoid heart disease and at least moderate valvular involvement. Participating centers will identify consecutive eligible patients treated within predefined study periods to minimize selection bias. The registry reflects real-world clinical practice and does not mandate any additional diagnostic or therapeutic interventions beyond standard of care.

The study population consists of adult patients with a confirmed diagnosis of neuroendocrine tumor consistent with carcinoid tumor and evidence of carcinoid-related cardiac involvement. Cardiac involvement is established by echocardiographic documentation of at least moderate valvular dysfunction in conjunction with morphological features typical of fibrotic degeneration. Elevated NT-proBNP levels are required to support the presence of hemodynamic significance. In patients undergoing cardiac surgery, histopathological confirmation of carcinoid-related fibrosis will be recorded when available.

A standardized data collection framework will be applied across centers. Baseline demographic data include age, sex, body mass index, and relevant cardiovascular risk factors. Comorbid conditions such as hypertension, diabetes mellitus, chronic kidney disease, chronic liver disease, and prior cardiovascular events will be documented. Functional status will be assessed using available clinical classifications, including New York Heart Association (NYHA) class where recorded.

Comprehensive echocardiographic data will form a core component of the registry. Parameters to be collected include qualitative and quantitative assessment of tricuspid and pulmonary valve morphology and function, evaluation of left-sided valves when involved, right and left ventricular dimensions and systolic function, atrial size, inferior vena cava dimensions, and estimation of pulmonary artery pressures. When available, advanced imaging modalities (e.g., three-dimensional echocardiography or cardiac magnetic resonance imaging) will be documented, but their use is not mandated by the protocol.

Oncological variables will include primary tumor location, histopathological grade (if available), presence and distribution of metastases (hepatic, lymph node, bone, cardiac, or other), biochemical activity, and prior or ongoing systemic therapies. These may include somatostatin analogs, targeted therapies, peptide receptor radionuclide therapy, chemotherapy, and surgical resection of the primary tumor or metastases. Temporal relationships between oncological diagnosis, onset of carcinoid syndrome, and detection of cardiac involvement will be analyzed when data permit.

Cardiac management strategies will be recorded in detail. This includes medical therapy for heart failure, timing and type of surgical valve interventions, and the use of transcatheter approaches. For patients evaluated for transcatheter procedures, anatomical considerations, procedural planning parameters, and heart team decisions will be documented where available. Procedural outcomes, in-hospital course, and short-term follow-up data will be collected in accordance with local documentation standards.

The primary objective of the registry is descriptive: to define the clinical, echocardiographic, and oncological profile of patients with moderate to severe carcinoid heart disease in a contemporary, multicenter cohort. Secondary objectives include identification of clinical and imaging features associated with advanced right ventricular dysfunction, exploration of factors associated with referral for surgical versus transcatheter intervention, and assessment of early clinical outcomes following different management strategies.

Where longitudinal data are available, follow-up analyses will evaluate survival, heart failure progression, need for repeat interventions, and changes in functional status. A predefined subgroup analysis will focus on patients undergoing transcatheter valve therapies to assess feasibility, safety, and short- to mid-term effectiveness in this specific population.

Data will be anonymized at the site level before central aggregation. Each participating center will obtain appropriate approval from its institutional ethics or bioethics committee in accordance with national regulations. Given the retrospective and observational nature of the registry, no study-specific interventions are performed, and patient management remains entirely at the discretion of the treating physicians.

By systematically collecting and analyzing real-world data from multiple centers, this registry aims to enhance understanding of carcinoid heart disease, improve risk stratification, and support evidence-based decision-making regarding timing and type of valvular intervention. The results are expected to inform future prospective studies and contribute to the development of interdisciplinary care pathways integrating cardiology and oncology expertise in the management of this complex condition.

03

Conditions studied

  • Carcinoid Heart Disease
  • Neuroendocrine Tumors
  • Carcinoid Syndrome
  • Valvular Heart Disease Patients

Keywords

  • Carcinoid Heart Disease
  • Neuroendocrine Tumor
  • Carcinoid Syndrome
  • Valvular Heart Disease
  • Transcatheter Tricuspid Valve Intervention
  • Observational Study
  • Multicenter Registry
  • Right-Sided Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of adult patients with carcinoid heart disease who are evaluated and treated at multiple tertiary cardiology and oncology centers across Poland, including the National Institute of Cardiology. Patients included in this registry represent a real-world, multicenter cohort of individuals with neuroendocrine tumors complicated by moderate to severe valvular heart disease. Data are collected retrospectively from consecutive patients meeting eligibility criteria, reflecting standard clinical practice and management of cardiac and oncologic care. The population includes both patients managed conservatively and those considered for surgical or transcatheter valve interventions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years.
  • Confirmed diagnosis of a neuroendocrine tumor consistent with carcinoid heart disease.
  • Echocardiographic evidence of at least moderate valvular disease associated with endocardial fibrosis.
  • Elevated NT-proBNP levels (>260 ng/L) consistent with cardiac dysfunction.
  • Availability of relevant clinical, echocardiographic, and laboratory data.
  • For patients who underwent cardiac surgery, histopathological confirmation of carcinoid-related cardiac tissue (if available).
  • Ability to provide for participation in the registry (or waiver as per local ethics approval for retrospective data).

Exclusion criteria

Exclusion Criteria:

  • Patients with insufficient clinical or imaging data to confirm carcinoid heart disease.
  • Presence of other primary cardiac conditions causing significant valvular disease unrelated to carcinoid syndrome (e.g., rheumatic heart disease, congenital valve disease)
  • Active participation in interventional clinical trials that would conflict with registry data collection
  • Patients younger than 18 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
120 participants (estimated)
Patient registry
No

Interventions

  • OtherObservational Registry of Carcinoid Heart Disease

    This study is a multicenter, retrospective, observational registry of patients with carcinoid heart disease. The "intervention" consists of systematic collection and analysis of clinical, echocardiographic, and laboratory data, including demographic characteristics, cardiovascular risk factors, tumor features, metastatic status, and prior or planned cardiac and oncologic treatments. Detailed echocardiographic assessment of valve structure and function, chamber dimensions, and ventricular performance will be performed. The registry also identifies patients potentially eligible for transcatheter valve interventions. No experimental treatment is administered; all patient management follows standard clinical practice.

06

What researchers measure

Primary outcomes

  1. Characterization of patients with carcinoid heart disease

    Characterization of patients with carcinoid heart disease defined as: presence of neuroendocrine tumor with hepatic metastases, echocardiographic evidence of right-sided valvular disease (tricuspid and/or pulmonary valve involvement), and biochemical evidence of serotonin excess (elevated urinary 5-HIAA or serum serotonin)

    Time frame: At baseline (time of registry enrollment or most recent echocardiogram)

Secondary outcomes

  1. Identification of patients eligible for transcatheter valve interventions

    Identification of candidates for transcatheter tricuspid or pulmonary valve replacement/repair among patients with carcinoid heart disease, assessed by echocardiography, CT-based anatomical evaluation and multidisciplinary Heart Team decision

    Time frame: Baseline

  2. Assessment of clinical factors associated with advanced valvular dysfunction

    Identification of clinical factors associated with advanced valvular dysfunction in carcinoid heart disease, assessed by urinary 5-HIAA level (µmol/24h), NT-proBNP (pg/mL) and NYHA functional class

    Time frame: Baseline

  3. Assessment of echocardiographic factors associated with advanced valvular dysfunction

    Identification of echocardiographic factors associated with advanced valvular dysfunction in carcinoid heart disease, assessed by tricuspid regurgitation grade and pulmonary valve function on transthoracic echocardiography

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data (IPD) will be entered into a secure electronic case report form (eCRF) provided by the scientific platform of the Polish Cardiac Society (Polskie Towarzystwo Kardiologiczne). All patient data will be fully anonymized before entry to protect privacy. The eCRF will be accessible to all participating centers. De-identified datasets may be shared with qualified researchers upon reasonable request, following approval by the registry steering committee and local ethics boards, in compliance with applicable national and institutional regulations.

Supporting information: Study protocol, Statistical analysis plan

Time frame: June 2026 - June 2027

Access criteria: Access to de-identified individual participant data (IPD) and supporting information (study protocol and statistical analysis plan) will be granted to qualified researchers upon reasonable request. Requests will be reviewed and approved by the registry steering committee and relevant local ethics boards. Approved researchers will have access to anonymized clinical, echocardiographic, laboratory, and treatment data through secure transfer or controlled access via the eCRF platform provided by the scientific platform of the Polish Cardiac Society. Data use will be governed by a data use agreement specifying conditions for confidentiality, publication, and compliance with applicable national and institutional regulations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Mar 4, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2027
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07450287
Lead sponsor
National Institute of Cardiology, Warsaw, Poland
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Mar 4, 2026

Study contacts

Piotr N Rudziński, MD, PhD
Contact
piotr.rudzinski@ikard.pl
+48608499737

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion